The Jumonjd3 protein is a sort of nervous system regulator, allowing stem cells to become neural cells. Researchers from the IFOM-IEO Campus of the European Institute of Oncology (EIO) in Milan, whose studies were published in Plos One magazine discovered the regulator protein. The researchers explained that the protein is an enzyme capable of activating the stem cell genes necessary to differentiate a cell into a nervous system cell.
The result, underlined the scientists led by Giusepe Testa, “adds an important perspective to understanding the intricate mechanisms of stem cell function.” This protein could soon become “a target to improve
Although a growing number of people today are stricken with cancer – the leading cause of death in France since 2004 – their risk of succumbing to this disease is dropping. Nationwide mortality rates continue to vary, most notably on a regional level, as was demonstrated in the distinguished Atlas de la mortalité par cancer en France metropolitaine [Atlas of cancer death in mainland France (excluding overseas territories)], published on January 28. On a generalized basis, the numbers for Northern and Central France clearly point to hypermortality while death rates in the southern portion of the country were lower
Cancer patients in remission at a Suffolk hospital can have their own cells transplanted back to them with the use of a new piece of equipment.
The stem-cell bath defrosts frozen cells taken from people recovering from blood cancers myeloma, leukaemia and lymphoma at Ipswich Hospital.
When transplanted back to the patient following treatment the cells can help their body create new bone marrow.
The bath cuts down on the need for patients to travel to other hospitals.
The stem cells are stored at -190C in liquid nitrogen and can be kept for several years at the national blood transfusion centre in Cambridge.
Pluristem Therapeutics, a leading developer of placenta-based cell therapy products, announced today that it has been issued Patent No. EP2366775B1, titled “Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy”, by the European Patent Office. This patent addresses use of adherent stromal cells from placenta or adipose tissue, expanded according to Pluristem’s methods of three dimensional culturing, for treating conditions that may benefit from facilitation of hematopoietic stem cell engraftment.
As described in the patent, Pluristem’s therapeutic cells are designed to promote the success of hematopoietic stem cell transplantation, which is used to treat
Historic Hurd Hall on Johns Hopkins’ East Baltimore campus was filled to capacity on Jan. 13 with students, faculty and staff waiting to hear five scientists—all in the early part of their careers—describe their novel ideas on how to cure metastatic cancer.
The five were finalists, chosen from among 44 entrants, in a competition on creative thinking named for John Rangos Sr., chairman of the Rangos Family Foundation, who funded the awards. Each scientist had 10 minutes to present his or her idea and answer questions from a panel of faculty judges, who would select the winners based on the